Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib versus osimertinib by immune biomarker in EGFR-mutant NSCLC
jRCTs031190221Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of afatinib and osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: 3-year survival rate and Immunological biomarker exploratory analysis. Started May 2020; status: completed.
02
Drugs
afatinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031190221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190221.